Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ascendis Pharma (ASND)
NASDAQ:ASND
Earnings Data
Report Date
May 21, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-1.45Last Year’s EPS
-2.4Same Quarter Last Year
Strong Buy
Based on 14 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 12, 2025
|% Change Since: 22.97%
|Next Earnings Date:May 21, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial growth and successful product launches, particularly with YORVIPATH in the U.S., and promising developments in the pipeline. However, challenges remain with revenue fluctuations for SKYTROFA and market penetration hurdles for YORVIPATH.Company Guidance
During the fourth quarter and full year 2024 earnings call, Ascendis Pharma provided detailed guidance and metrics reflecting their strong market position and future growth potential. Key highlights included SKYTROFA's impressive performance, achieving around €200 million in revenue and a 6.5% market share in the U.S. growth hormone market, alongside a dominant 45% share in the U.S. long-acting segment. The company expressed confidence in further market penetration and multiple planned commercial launches across various indications and countries. YORVIPATH, now launched in the U.S., showed promising early demand with 908 prescriptions from 539 unique prescribers, indicating its potential to become a multi-billion-dollar product. Financially, Ascendis ended 2024 with €665 million in cash, positioning them to invest in commercial uptake and new product development. They remain optimistic about sustained revenue growth, bolstered by upcoming regulatory submissions for TransCon CNP and strategic collaborations with Novo Nordisk.Strong Financial Position and Revenue Growth
Ascendis Pharma ended 2024 with a strong financial position, holding €665 million in cash, including a $100 million upfront payment from Novo Nordisk. Total revenue for 2024 was €363.6 million, with SKYTROFA achieving revenue of around €200 million, a significant increase supported by an 84% volume increase in the U.S.
Successful Launch of YORVIPATH in the U.S.
YORVIPATH, the only FDA-approved treatment for hypothyroidism in adults, has launched in the U.S. and has already shown strong initial demand with 908 patient prescriptions as of February 7, 2025. The product is expected to grow into a multi-billion-dollar product over time.
Positive Developments in Pipeline
TransCon CNP clinical data demonstrated potential as a highly differentiated product for achondroplasia, with plans to submit an NDA for its treatment in Q1 2025. Additionally, a combination treatment with TransCon Growth Hormone is in development.
Expansion Beyond Endocrine Rare Diseases
Ascendis Pharma is expanding its TransCon technology platform beyond endocrine rare diseases, collaborating with Novo Nordisk in metabolic diseases, and forming Eyconis for ophthalmology therapies.
---
ASND Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ASND Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 12, 2025 | $126.14 | $142.49 | +12.96% |
| Nov 14, 2024 | $124.28 | $126.51 | +1.79% |
| Sep 03, 2024 | $134.68 | $119.50 | -11.27% |
| May 02, 2024 | $141.10 | $137.20 | -2.76% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Ascendis Pharma (ASND) report earnings?
Ascendis Pharma (ASND) is schdueled to report earning on May 21, 2025, TBA Not Confirmed.
What is Ascendis Pharma (ASND) earnings time?
Ascendis Pharma (ASND) earnings time is at May 21, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ASND EPS forecast?
ASND EPS forecast for the fiscal quarter 2025 (Q1) is -1.45.
---